FDA: iRhythm targeted heart monitor at ‘high-risk’ patients without seeking clearance

The U.S. Food and Drug Administration has published its warning letter to iRhythm Technologies, revealing inspectors accused the company of failing to seek clearance before making major changes to permitted uses for its Zio AT heart monitor.